{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:47:43Z","timestamp":1791578863874,"version":"4.3.4"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81972729"],"award-info":[{"award-number":["81972729"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81971811"],"award-info":[{"award-number":["81971811"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81802095"],"award-info":[{"award-number":["81802095"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81602910"],"award-info":[{"award-number":["81602910"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science and Technological Supports Project of Sichuan Province","award":["2017FZ0043"],"award-info":[{"award-number":["2017FZ0043"]}]},{"name":"Science and Technological Supports Project of Sichuan Province","award":["2019YFS0372"],"award-info":[{"award-number":["2019YFS0372"]}]},{"name":"Science and Technological Supports Project of Sichuan Province","award":["2019YFS0370"],"award-info":[{"award-number":["2019YFS0370"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Sunitinib, a receptor tyrosine kinase (RTK) inhibitor that targets multiple receptors such as vascular endothelial growth factor receptors (VEGFRs), was approved for cancer treatment in 2006. However, it was unsuccessful in treating certain cancers, particularly metastatic breast cancer (MBC), and the mechanism underlying this \u201csunitinib resistance\u201d remains unclear. Herein, we investigated whether the sunitinib-associated inferior survival benefit in MBC was due to sunitinib-induced endothelial cell (EC) injury or EC senescence.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>4T1 murine breast cancer cells were used as the main breast tumor model for it produces a highly metastatic solid tumor that can spontaneously metastasize to the lung, which closely mimics highly metastatic human breast cancer. Senescence-associated \u03b2-galactosidase (SA-\u03b2-Gal, immunohistochemistry [IHC]-staining), P16, P53, and P57 (immunoblotting) were used as markers of cell senescence. A protein array containing 25 senescence-associated chemokines and the transwell chemotaxis assay were used to examine whether sunitinib increases inflammatory chemokine secretion which attracts tumor cells via chemokinesis. Flow cytometry and IHC were used to detect whether the sunitinib-induced senescent ECs recruit cancer-associated inflammatory myeloid cells. Finally, the spontaneous metastatic model was used to monitor whether sunitinib causes the formation of \u201cpre-metastatic niche\u201d which promotes MBC to metastasize to the lungs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We demonstrated that sunitinib induced a senescence-like endothelial cell (EC) phenotype. Inflammatory chemokine secretion and VCAM1 expression were significantly increased in senescent ECs, resulting in tumor cell (TC) chemotaxis and TC\/EC interactions. Meanwhile, EC senescence caused loosening of EC junctions, facilitating TC transmigration through the endothelial barrier. Sunitinib-induced senescent ECs also recruited cancer-associated myeloid cells to form a \u201cpre-metastatic niche\u201d-like microenvironment. Alterations at the molecular level and in the tissue environment ultimately led to an increase in distant metastasis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Although sunitinib was designed to target the EC directly, the increase in tumor metastasis may ironically be due to sunitinib \u201ccorrectly\u201d playing its role. Our findings suggest that we should carefully weigh the pros and cons before using sunitinib and other antiangiogenic drugs that directly target the ECs.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13058-020-01346-y","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T14:04:04Z","timestamp":1601388244000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Sunitinib facilitates metastatic breast cancer spreading by inducing endothelial cell senescence"],"prefix":"10.1186","volume":"22","author":[{"given":"Denian","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongxue","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingmiao","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong\u2019gang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haili","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7588-7249","authenticated-orcid":false,"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,29]]},"reference":[{"issue":"5","key":"1346_CR1","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374.","journal-title":"Cell"},{"key":"1346_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev.med.57.121304.131306","volume":"57","author":"J Folkman","year":"2006","unstructured":"Folkman J. Angiogenesis. Annu Rev Med. 2006;57:1\u201318.","journal-title":"Annu Rev Med"},{"issue":"7","key":"1346_CR3","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/nrc2868","volume":"10","author":"AS Chung","year":"2010","unstructured":"Chung AS, Lee J, Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer. 2010;10(7):505\u201314.","journal-title":"Nat Rev Cancer"},{"issue":"7070","key":"1346_CR4","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nature04483","volume":"438","author":"N Ferrara","year":"2005","unstructured":"Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005;438(7070):967\u201374.","journal-title":"Nature"},{"issue":"3","key":"1346_CR5","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.critrevonc.2014.07.006","volume":"92","author":"FM Guida","year":"2014","unstructured":"Guida FM, Santoni M, Conti A, Burattini L, Savini A, Zeppola T, Caricato M, Cascinu S, Tonini G, Santini D. Alternative dosing schedules for sunitinib as a treatment of patients with metastatic renal cell carcinoma. Crit Rev Oncol Hemat. 2014;92(3):208\u201317.","journal-title":"Crit Rev Oncol Hemat"},{"issue":"4","key":"1346_CR6","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s10456-012-9291-z","volume":"15","author":"JC Welti","year":"2012","unstructured":"Welti JC, Powles T, Foo S, Gourlaouen M, Preece N, Foster J, Frentzas S, Bird D, Sharpe K, van Weverwijk A, et al. Contrasting effects of sunitinib within in vivo models of metastasis. Angiogenesis. 2012;15(4):623\u201341.","journal-title":"Angiogenesis"},{"issue":"5","key":"1346_CR7","doi-asserted-by":"publisher","first-page":"471","DOI":"10.4161\/cbt.2.5.446","volume":"2","author":"TJ Abrams","year":"2003","unstructured":"Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther. 2003;2(5):471\u20138.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"1346_CR8","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1172\/JCI84386","volume":"127","author":"M Elgendy","year":"2017","unstructured":"Elgendy M, Abdel-Aziz AK, Renne SL, Bornaghi V, Procopio G, Colecchia M, Kanesvaran R, Toh CK, Bossi D, Pallavicini I, et al. Dual modulation of MCL-1 and mTOR determines the response to sunitinib. J Clin Invest. 2017;127(1):153\u201368.","journal-title":"J Clin Invest"},{"issue":"23","key":"1346_CR9","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.1200\/JCO.2012.43.3391","volume":"31","author":"JP Crown","year":"2013","unstructured":"Crown JP, Dieras V, Staroslawska E, Yardley DA, Bachelot T, Davidson N, Wildiers H, Fasching PA, Capitain O, Ramos M, et al. Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. J Clin Oncol. 2013;31(23):2870\u20138.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1346_CR10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10549-010-0788-0","volume":"121","author":"CH Barrios","year":"2010","unstructured":"Barrios CH, Liu MC, Lee SC, Vanlemmens L, Ferrero JM, Tabei T, Pivot X, Iwata H, Aogi K, Lugo-Quintana R, et al. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat. 2010;121(1):121\u201331.","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"1346_CR11","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1200\/JCO.2011.35.7376","volume":"30","author":"J Bergh","year":"2012","unstructured":"Bergh J, Bondarenko IM, Lichinitser MR, Liljegren A, Greil R, Voytko NL, Makhson AN, Cortes J, Lortholary A, Bischoff J, et al. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. J Clin Oncol. 2012;30(9):921\u20139.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1346_CR12","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s10549-010-1066-x","volume":"123","author":"H Wildiers","year":"2010","unstructured":"Wildiers H, Fontaine C, Vuylsteke P, Martens M, Canon JL, Wynendaele W, Focan C, De Greve J, Squifflet P, Paridaens R. Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer. Breast Cancer Res Treat. 2010;123(2):463\u20139.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"1346_CR13","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ccr.2009.01.021","volume":"15","author":"JM Ebos","year":"2009","unstructured":"Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009;15(3):232\u20139.","journal-title":"Cancer Cell"},{"issue":"2\u20133","key":"1346_CR14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3233\/BD-160218","volume":"36","author":"A Elgebaly","year":"2016","unstructured":"Elgebaly A, Menshawy A, El Ashal G, Osama O, Ghanem E, Omar A, Negida A. Sunitinib alone or in combination with chemotherapy for the treatment of advanced breast cancer: a systematic review and meta-analysis. Breast Dis. 2016;36(2\u20133):91\u2013101.","journal-title":"Breast Dis"},{"issue":"2","key":"1346_CR15","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/nrc2791","volume":"10","author":"JM Butler","year":"2010","unstructured":"Butler JM, Kobayashi H, Rafii S. Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. Nat Rev Cancer. 2010;10(2):138\u201346.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"1346_CR16","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/nrc1044","volume":"3","author":"CA Schmitt","year":"2003","unstructured":"Schmitt CA. Senescence apoptosis and therapy - cutting the lifelines of cancer. Nat Rev Cancer. 2003;3(4):286\u201395.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"1346_CR17","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.cell.2008.03.039","volume":"133","author":"T Kuilman","year":"2008","unstructured":"Kuilman T, Michaloglou C, Vredeveld LC, Douma S, van Doorn R, Desmet CJ, Aarden LA, Mooi WJ, Peeper DS. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell. 2008;133(6):1019\u201331.","journal-title":"Cell"},{"key":"1346_CR18","doi-asserted-by":"crossref","unstructured":"Zhang BY, Fu D, Xu QX, Cong XL, Wu CY, Zhong XM, Ma YS, Lv ZW, Chen F, Han L, et al. The senescence-associated secretory phenotype is potentiated by feedforward regulatory mechanisms involving Zscan4 and TAK1. Nat Commun. 2018;9(1):1723.","DOI":"10.1038\/s41467-018-04010-4"},{"issue":"12","key":"1346_CR19","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1371\/journal.pbio.0060301","volume":"6","author":"JP Coppe","year":"2008","unstructured":"Coppe JP, Patil CK, Rodier F, Sun Y, Munoz DP, Goldstein J, Nelson PS, Desprez PY, Campisi J. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 2008;6(12):2853\u201368.","journal-title":"PLoS Biol"},{"issue":"3","key":"1346_CR20","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ccell.2017.01.007","volume":"31","author":"E Wieland","year":"2017","unstructured":"Wieland E, Rodriguez-Vita J, Liebler SS, Mogler C, Moll I, Herberich SE, Espinet E, Herpel E, Menuchin A, Chang-Claude J, et al. Endothelial Notch1 activity facilitates metastasis. Cancer Cell. 2017;31(3):355\u201367.","journal-title":"Cancer Cell"},{"issue":"11","key":"1346_CR21","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1593\/neo.06493","volume":"8","author":"J Heimburg","year":"2006","unstructured":"Heimburg J, Yan J, Morey S, Glinskii OV, Huxley VH, Wild L, Klick R, Roy R, Glinsky VV, Rittenhouse-Olson K. Inhibition of spontaneous breast cancer metastasis by anti-Thomsen-Friedenreich antigen monoclonal antibody JAA-F11. Neoplasia. 2006;8(11):939\u201348.","journal-title":"Neoplasia"},{"issue":"7","key":"1346_CR22","first-page":"1486","volume":"58","author":"BA Pulaski","year":"1998","unstructured":"Pulaski BA, Ostrand-Rosenberg S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res. 1998;58(7):1486\u201393.","journal-title":"Cancer Res"},{"issue":"20","key":"1346_CR23","doi-asserted-by":"publisher","first-page":"9363","DOI":"10.1073\/pnas.92.20.9363","volume":"92","author":"GP Dimri","year":"1995","unstructured":"Dimri GP, Lee XH, Basile G, Acosta M, Scott C, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereirasmith O, et al. A biomarker that identifies senescent human-cells in culture and in aging skin in-vivo. P Natl Acad Sci USA. 1995;92(20):9363\u20137.","journal-title":"P Natl Acad Sci USA"},{"issue":"20","key":"1346_CR24","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1093\/jnci\/djq364","volume":"102","author":"JA Ewald","year":"2010","unstructured":"Ewald JA, Desotelle JA, Wilding G, Jarrard DF. Therapy-induced senescence in cancer. J Natl Cancer I. 2010;102(20):1536\u201346.","journal-title":"J Natl Cancer I"},{"issue":"8","key":"1346_CR25","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/ncb2784","volume":"15","author":"JC Acosta","year":"2013","unstructured":"Acosta JC, Banito A, Wuestefeld T, Georgilis A, Janich P, Morton JP, Athineos D, Kang TW, Lasitschka F, Andrulis M, et al. A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat Cell Biol. 2013;15(8):978\u201390.","journal-title":"Nat Cell Biol"},{"issue":"4","key":"1346_CR26","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2217\/hep-2017-0011","volume":"4","author":"TF Greten","year":"2017","unstructured":"Greten TF, Eggert T. Cellular senescence associated immune responses in liver cancer. Hepatic Oncol. 2017;4(4):123\u20137.","journal-title":"Hepatic Oncol"},{"issue":"9","key":"1346_CR27","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nri3049","volume":"11","author":"A Zlotnik","year":"2011","unstructured":"Zlotnik A, Burkhardt AM, Homey B. Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol. 2011;11(9):597\u2013606.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"1346_CR28","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.2337\/db16-0152","volume":"65","author":"GL King","year":"2016","unstructured":"King GL, Park K, Li Q. Selective insulin resistance and the development of cardiovascular diseases in diabetes: the 2015 Edwin Bierman Award Lecture. Diabetes. 2016;65(6):1462\u201371.","journal-title":"Diabetes"},{"issue":"12","key":"1346_CR29","first-page":"3233","volume":"54","author":"H Okahara","year":"1994","unstructured":"Okahara H, Yagita H, Miyake K, Okumura K. Involvement of very late activation antigen 4 (VLA-4) and vascular cell adhesion molecule 1 (VCAM-1) in tumor necrosis factor alpha enhancement of experimental metastasis. Cancer Res. 1994;54(12):3233\u20136.","journal-title":"Cancer Res"},{"key":"1346_CR30","doi-asserted-by":"publisher","first-page":"6993","DOI":"10.1038\/ncomms7993","volume":"6","author":"M Tichet","year":"2015","unstructured":"Tichet M, Prod\u2019Homme V, Fenouille N, Ambrosetti D, Mallavialle A, Cerezo M, Ohanna M, Audebert S, Rocchi S, Giacchero D, et al. Tumour-derived SPARC drives vascular permeability and extravasation through endothelial VCAM1 signalling to promote metastasis. Nat Commun. 2015;6:6993.","journal-title":"Nat Commun"},{"issue":"1","key":"1346_CR31","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1152\/japplphysiol.91353.2008","volume":"106","author":"JD Erusalimsky","year":"2009","unstructured":"Erusalimsky JD. Vascular endothelial senescence: from mechanisms to pathophysiology. J Appl Physiol. 2009;106(1):326\u201332.","journal-title":"J Appl Physiol"},{"issue":"7069","key":"1346_CR32","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/nature04186","volume":"438","author":"RN Kaplan","year":"2005","unstructured":"Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005;438(7069):820\u20137.","journal-title":"Nature"},{"issue":"3\u20134","key":"1346_CR33","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s10555-013-9420-1","volume":"32","author":"J Sceneay","year":"2013","unstructured":"Sceneay J, Smyth MJ, Moller A. The pre-metastatic niche: finding common ground. Cancer Metastasis Rev. 2013;32(3\u20134):449\u201364.","journal-title":"Cancer Metastasis Rev"},{"issue":"4","key":"1346_CR34","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/ijc.29444","volume":"137","author":"CF Wu","year":"2015","unstructured":"Wu CF, Andzinski L, Kasnitz N, Kroger A, Klawonn F, Lienenklaus S, Weiss S, Jablonska J. The lack of type I interferon induces neutrophil-mediated pre-metastatic niche formation in the mouse lung. Int J Cancer. 2015;137(4):837\u201347.","journal-title":"Int J Cancer"},{"issue":"4","key":"1346_CR35","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nrd2012","volume":"5","author":"M Atkins","year":"2006","unstructured":"Atkins M, Jones CA, Kirkpatrick P. Sunitinib maleate. Nat Rev Drug Discov. 2006;5(4):279\u201380.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"1346_CR36","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.tranon.2014.02.007","volume":"7","author":"T Yin","year":"2014","unstructured":"Yin T, He S, Ye T, Shen G, Wan Y, Wang Y. Antiangiogenic therapy using sunitinib combined with rapamycin retards tumor growth but promotes metastasis. Transl Oncol. 2014;7(2):221\u20139.","journal-title":"Transl Oncol"},{"issue":"12","key":"1346_CR37","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.15252\/emmm.201403989","volume":"6","author":"JM Ebos","year":"2014","unstructured":"Ebos JM, Mastri M, Lee CR, Tracz A, Hudson JM, Attwood K, Cruz-Munoz WR, Jedeszko C, Burns P, Kerbel RS. Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy. EMBO Mol Med. 2014;6(12):1561\u201376.","journal-title":"EMBO Mol Med"},{"issue":"4","key":"1346_CR38","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1158\/0008-5472.CAN-16-1982","volume":"77","author":"JW Wragg","year":"2017","unstructured":"Wragg JW, Heath VL, Bicknell R. Sunitinib treatment enhances metastasis of innately drug-resistant breast tumors. Cancer Res. 2017;77(4):1008\u201320.","journal-title":"Cancer Res"},{"key":"1346_CR39","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/1476-4598-13-207","volume":"13","author":"D Zhang","year":"2014","unstructured":"Zhang D, Sun B, Zhao X, Ma Y, Ji R, Gu Q, Dong X, Li J, Liu F, Jia X, et al. Twist1 expression induced by sunitinib accelerates tumor cell vasculogenic mimicry by increasing the population of CD133+ cells in triple-negative breast cancer. Mol Cancer. 2014;13:207.","journal-title":"Mol Cancer"},{"key":"1346_CR40","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/2045-824X-6-12","volume":"6","author":"E Chinchar","year":"2014","unstructured":"Chinchar E, Makey KL, Gibson J, Chen F, Cole SA, Megason GC, Vijayakumar S, Miele L, Gu JW. Sunitinib significantly suppresses the proliferation, migration, apoptosis resistance, tumor angiogenesis and growth of triple-negative breast cancers but increases breast cancer stem cells. Vasc Cell. 2014;6:12.","journal-title":"Vasc Cell"},{"issue":"1","key":"1346_CR41","doi-asserted-by":"publisher","first-page":"62","DOI":"10.2174\/1568009616666161025114914","volume":"17","author":"S Braga","year":"2017","unstructured":"Braga S, Cardoso J, Andre S, Brito M, Sanchez P, Orvalho L, Salgado L, Dias S, Pereira-Leal JB, Passos-Coelho JL. Does hypoxic response mediate primary resistance to sunitinib in untreated locally advanced breast cancer? Curr Cancer Drug Targets. 2017;17(1):62\u201373.","journal-title":"Curr Cancer Drug Targets"},{"issue":"4","key":"1346_CR42","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/path.4052","volume":"227","author":"AS Chung","year":"2012","unstructured":"Chung AS, Kowanetz M, Wu X, Zhuang G, Ngu H, Finkle D, Komuves L, Peale F, Ferrara N. Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors. J Pathol. 2012;227(4):404\u201316.","journal-title":"J Pathol"},{"issue":"9","key":"1346_CR43","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1038\/bjc.2017.69","volume":"116","author":"MJ Bueno","year":"2017","unstructured":"Bueno MJ, Mouron S, Quintela-Fandino M. Personalising and targeting antiangiogenic resistance: a complex and multifactorial approach. Br J Cancer. 2017;116(9):1119\u201325.","journal-title":"Br J Cancer"},{"issue":"5","key":"1346_CR44","doi-asserted-by":"publisher","first-page":"e1217368","DOI":"10.1080\/23723556.2016.1217368","volume":"3","author":"M Quintela-Fandino","year":"2016","unstructured":"Quintela-Fandino M. Normoxic or hypoxic adaptation in response to antiangiogenic therapy: clinical implications. Mol Cell Oncol. 2016;3(5):e1217368.","journal-title":"Mol Cell Oncol"},{"issue":"4","key":"1346_CR45","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1097\/PPO.0000000000000134","volume":"21","author":"RS Kerbel","year":"2015","unstructured":"Kerbel RS. A decade of experience in developing preclinical models of advanced- or early-stage spontaneous metastasis to study antiangiogenic drugs, metronomic chemotherapy, and the tumor microenvironment. Cancer J. 2015;21(4):274\u201383.","journal-title":"Cancer J"},{"issue":"17","key":"1346_CR46","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.1158\/0008-5472.CAN-15-0308","volume":"75","author":"JM Ebos","year":"2015","unstructured":"Ebos JM. Prodding the beast: assessing the impact of treatment-induced metastasis. Cancer Res. 2015;75(17):3427\u201335.","journal-title":"Cancer Res"},{"issue":"7","key":"1346_CR47","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1084\/jem.20141836","volume":"212","author":"T Kitamura","year":"2015","unstructured":"Kitamura T, Qian BZ, Soong D, Cassetta L, Noy R, Sugano G, Kato Y, Li J, Pollard JW. CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages. J Exp Med. 2015;212(7):1043\u201359.","journal-title":"J Exp Med"},{"issue":"7355","key":"1346_CR48","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature10138","volume":"475","author":"BZ Qian","year":"2011","unstructured":"Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, Kaiser EA, Snyder LA, Pollard JW. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011;475(7355):222\u20135.","journal-title":"Nature"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-020-01346-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-020-01346-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-020-01346-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T23:53:37Z","timestamp":1632873217000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-020-01346-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,29]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1346"],"URL":"https:\/\/doi.org\/10.1186\/s13058-020-01346-y","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,29]]},"assertion":[{"value":"22 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The animal experiments were approved by the Animal Ethics Committee of Sichuan University and performed according to the institutional and national guidelines.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This manuscript has been approved by all of the authors who are properly listed and identified and by the institution where the work was carried out.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"There are no competing interests among the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"103"}}